What is Nabla Bio?
Nabla Bio is a biotechnology firm headquartered in Cambridge, Massachusetts, operating within the dynamic life sciences industry. The company is focused on leveraging advanced scientific research and development to address critical challenges in human health. Its strategic positioning within the biotechnology ecosystem suggests a commitment to innovation and the advancement of novel therapeutic solutions. The scale of its recent investment indicates a transition towards significant scaling and market penetration.
How much funding has Nabla Bio raised?
Nabla Bio has raised a total of $37M across 2 funding rounds:
Angel/Seed
$11M
Series A
$26M
Angel/Seed (2021): $11M with participation from Cantos Ventures, Khosla Ventures, Fifty Years, and Zetta Venture Partners
Series A (2024): $26M led by Bristol-Myers Squibb, AstraZeneca, Radical Ventures, and Takeda
Key Investors in Nabla Bio
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and manufacturing prescription medications for serious diseases, with expertise in oncology, cardiovascular disease, immunoscience, and virology. They invest in innovative treatments and collaborate to accelerate therapeutic advances.
AstraZeneca
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, and commercialization of medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. They are committed to scientific innovation in healthcare.
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies across various sectors including AI, fintech, health, and sustainable energy. They focus on supporting transformative innovations.
What's next for Nabla Bio?
With the recent infusion of capital, Nabla Bio is poised for accelerated growth and the expansion of its research and development initiatives. The strategic nature of this investment, particularly from established players in the pharmaceutical and venture capital spaces, signals strong confidence in the company's technological platform and future market potential. Nabla Bio is expected to focus on advancing its pipeline, potentially moving towards clinical trials and further commercialization efforts, solidifying its position as a key innovator in the biotechnology landscape.
See full Nabla Bio company page
